Oxford BioMedica gets TroVax green light

26th Jul 2010 13:39

Oxford Biomedica, which has traded between 9.10p and 12p all year, bounced off the lower end of its trading range on Monday after the gene therapy company announced significant regulatory approval for its TroVax drug.The US Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee (RAC) has given approval for Oxford to initiate a clinical Phase II study in the United States to assess the activity of TroVax (MVA-5T4) in patients with progressive hormone refractory prostate cancer (HRPC).The randomised, open-label Phase II study will enrol 80 patients with metastatic HRPC in five centres across the US and will assess the activity of TroVax plus chemotherapy drug Docetaxel versus Docetaxel alone. "We intend this study to be followed by a series of investigator-led clinical studies," said John Dawson, chief executive officer of Oxford BioMedica.